| scholarly article | Q13442814 |
| P50 | author | Arlene M Davis | Q42846902 |
| P2093 | author name string | Gabriel Lázaro-Muñoz | |
| Anya E R Prince | |||
| John M Conley | |||
| R Jean Cadigan | |||
| P2860 | cites work | Proposed shift in screening for breast cancer. | Q50963172 |
| The NCGENES project: exploring the new world of genome sequencing. | Q54473978 | ||
| Recommendations for returning genomic incidental findings? We need to talk! | Q26995124 | ||
| We screen newborns, don't we?: realizing the promise of public health genomics | Q27007571 | ||
| Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network | Q28673413 | ||
| A new initiative on precision medicine | Q29615654 | ||
| ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing | Q29616235 | ||
| Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics | Q30391601 | ||
| Returning pleiotropic results from genetic testing to patients and research participants | Q30575451 | ||
| Return of genomic results to research participants: the floor, the ceiling, and the choices in between | Q34000877 | ||
| Managing incidental findings and research results in genomic research involving biobanks and archived data sets | Q34205284 | ||
| Stewardship practices of U.S. biobanks | Q34288996 | ||
| Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology | Q34465792 | ||
| Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics | Q34544874 | ||
| Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium | Q35033000 | ||
| Genomic screening of the general adult population: key concepts for assessing net benefit with systematic evidence reviews. | Q35287751 | ||
| Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice | Q35825826 | ||
| A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing | Q36578258 | ||
| Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records | Q36592201 | ||
| The promise and peril of genomic screening in the general population | Q36880591 | ||
| Point-counterpoint. Patient autonomy and incidental findings in clinical genomics | Q37040336 | ||
| Point-counterpoint. Ethics and genomic incidental findings | Q37169821 | ||
| Return of secondary genomic findings vs patient autonomy: implications for medical care | Q37239957 | ||
| Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies | Q37590819 | ||
| Processes and factors involved in decisions regarding return of incidental genomic findings in research | Q37666159 | ||
| Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). | Q38242504 | ||
| Evidence, errors, and ethics. | Q38470039 | ||
| "Forward-Thinking" in U.S. Biobanking | Q39001963 | ||
| Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Children's Hospital Gene Partnership Informed Cohort Oversight Board | Q39276157 | ||
| Application of population screening principles to genetic screening for adult-onset conditions | Q40666787 | ||
| Premature guidance about whole-genome sequencing | Q42817703 | ||
| Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates | Q46136683 | ||
| The evidence dilemma in genomic medicine. | Q50769689 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 184-194 | |
| P577 | publication date | 2017-02-01 | |
| P1433 | published in | Genetic Testing and Molecular Biomarkers | Q15753742 |
| P1476 | title | Which Results to Return: Subjective Judgments in Selecting Medically Actionable Genes | |
| P478 | volume | 21 |
| Q47302919 | Age and perceived risks and benefits of preventive genomic screening |
| Q57455566 | Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group |
| Q95289292 | Genomics and Infectious Diseases: Expert Perspectives on Public Health Considerations regarding Actionability and Privacy |
| Q90597648 | Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial |
| Q57642752 | Improved ethical guidance for the return of results from psychiatric genomics research |
| Q56527776 | Incidental or secondary findings: an integrative and patient-inclusive approach to the current debate |
| Q89628704 | Is Real-Time ELSI Realistic? |
| Q47639707 | Online Education and e-Consent for GeneScreen, a Preventive Genomic Screening Study. |
| Q57306572 | Physicians’ perspectives on receiving unsolicited genomic results |
| Q57784513 | Psychiatric genetics researchers' views on offering return of results to individual participants |
| Q89870343 | Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer |
| Q89014435 | Returning negative results to individuals in a genomic screening program: lessons learned |
Search more.